financetom
Business
financetom
/
Business
/
--Deere Keeps Quarterly Dividend at $1.47 a Share; Payable Nov. 8 to Shareholders on Sept. 30
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Deere Keeps Quarterly Dividend at $1.47 a Share; Payable Nov. 8 to Shareholders on Sept. 30
Aug 28, 2024 9:21 AM

11:51 AM EDT, 08/28/2024 (MT Newswires) --

Price: 378.13, Change: +2.14, Percent Change: +0.57

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Volcon Regains Compliance With Nasdaq's Listing Requirements -- Shares Rise
Volcon Regains Compliance With Nasdaq's Listing Requirements -- Shares Rise
Jul 18, 2024
10:55 AM EDT, 07/18/2024 (MT Newswires) -- Volcon ( VLCN ) said Thursday it has been informed by Nasdaq that it has regained compliance with the stock exchange's listing rules. The company's shares were nearly 7% higher in recent trading. Price: 3.25, Change: +0.18, Percent Change: +5.70 ...
General Mills Appoints Chief Strategy & Growth Officer
General Mills Appoints Chief Strategy & Growth Officer
Jul 18, 2024
10:53 AM EDT, 07/18/2024 (MT Newswires) -- General Mills ( GIS ) said Thursday it has appointed Asheesh Saksena as chief strategy & growth officer, effective Aug. 26. Saksena succeeds Dana McNabb, following her prior appointment to group president, North America Retail, the firm said. He most recently served as chief growth officer for Gap (GPS). Price: 66.15, Change: +0.81,...
Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment
Ionis Pharmaceuticals Completes Trial Enrollment for Alexander Disease Treatment
Jul 18, 2024
10:54 AM EDT, 07/18/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Thursday it completed enrollment in a clinical trial of zilganersen, an investigational ribonucleic acid-targeted medicine to treat children and adults with Alexander disease, a neurological disorder. Topline data are expected in H2 2025. The study is the first trial to evaluate an investigational medicine designed to address...
Bristol Myers Squibb Validates Net-Zero Goals through Science Based Targets Initiative
Bristol Myers Squibb Validates Net-Zero Goals through Science Based Targets Initiative
Jul 18, 2024
10:55 AM EDT, 07/18/2024 (MT Newswires) -- Bristol Myers Squibb ( BMY ) said Thursday it has validated its near-term and longer-term targets to lower greenhouse emissions throughout its value chain to net-zero by 2050 through the Science Based Targets initiative. The drug maker announced its net-zero goal last year and also set several interim targets, including reducing its direct...
Copyright 2023-2026 - www.financetom.com All Rights Reserved